Literature DB >> 25201066

Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy.

Zhenchang Sun1, Xin Li, Xiaolong Wu, Xiaorui Fu, Ling Li, Lei Zhang, Yu Chang, Mingzhi Zhang.   

Abstract

We conducted a preliminarily study on the clinical characteristics of chronic lung injury (CLI) in patients with non-Hodgkin lymphoma (NHL) after CHOP chemotherapy and observed the effects of this injury on CHOP treatment efficacy. Sixty patients who were diagnosed as NHL and received CHOP chemotherapy in hospital were enrolled for this clinical trial. CLI was assessed by clinical symptoms and computed tomography (CT) scan conducted before and after chemotherapy. The effect of CLI on the efficacy of CHOP chemotherapy in patients with NHL was evaluated by comparing treatment response and recurrence rate to patients with no signs of lung injury. Our CT scans revealed multiple signs of CLI in 35 patients (56.67 %), such as pulmonary diffuse, limited infiltration shadow or ground glass-like changes. Among them, 23 patients (38.33 %) showed bilateral diffuse lung injury and 12 (20.00 %) showed topical lung injury. Most patients suffering from 6 to 12 months delayed recurrence exhibited signs of CLI. The inflammatory response of CLI may increase the risk of disease progression and recurrence. Therefore, early diagnosis and intervention, which play a positive role in the clinical treatment and the long-term efficacy, are critical for patients with NHL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201066     DOI: 10.1007/s13277-014-2582-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

Review 1.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

2.  Drug-induced lung disease: high-resolution CT and histological findings.

Authors:  Joanne R Cleverley; Nicholas J Screaton; Melanie P Hiorns; Julia D A Flint; Nestor L Müller
Journal:  Clin Radiol       Date:  2002-04       Impact factor: 2.350

3.  [Busulfan-induced pneumopathy].

Authors:  F Massin; A Fur; O Reybet-Degat; P Camus; L Jeannin
Journal:  Rev Mal Respir       Date:  1987       Impact factor: 0.622

Review 4.  Imaging the lungs in patients treated for lymphoma.

Authors:  H A Vargas; F A Hampson; J L Babar; A S Shaw
Journal:  Clin Radiol       Date:  2009-06-05       Impact factor: 2.350

Review 5.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

6.  IKKalpha at the crossroads of inflammation and metastasis.

Authors:  Nesrine I Affara; Lisa M Coussens
Journal:  Cell       Date:  2007-04-06       Impact factor: 41.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.